Immunological incompatibility as a basis for cancer curing and vaccination

Informacje na temat projektu

ULISES

Identyfikator umowy o grant: 899708

DOI

10.3030/899708

Projekt został zamknięty

Data podpisania przez KE 18 Czerwca 2020

Data rozpoczęcia 1 Października 2020

Data zakończenia 30 Czerwca 2024

Finansowanie w ramach

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Koszt całkowity

€ 2 977 160,00

Wkład UE

€ 2 977 160,00

Koordynowany przez

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Spain

CORDIS oferuje możliwość skorzystania z odnośników do publicznie dostępnych publikacji i rezultatów projektów realizowanych w ramach programów ramowych HORYZONT.

Odnośniki do rezultatów i publikacji związanych z poszczególnymi projektami 7PR, a także odnośniki do niektórych konkretnych kategorii wyników, takich jak zbiory danych i oprogramowanie, są dynamicznie pobierane z systemu OpenAIRE .

Rezultaty

Documents, reports (10)

Final report on Communication Activities

The report will provide a description of the implementation of the ULISES communication strategy, channels, formats, materials and the analysis of the generated impacts in terms of outreach and engagement.

Functionally tested pDNAs

Validation of the generated plasmids. Expression analysis and cellular response.

First set of potentially useful monoclonal anti-HLA-A antibodies

Description of a first set of potentially useful monoclonal antiHLAA antibodies capable of reacting against the alloHLA antigens expressed on the surface of tumour cells

In vitro testing of NPs in relevant cellular models

The final NPs (and control NPs) will be tested in relevant cellular models and tested in tumour organoids. The final NPs will be ready to be used in in vivo models in WP5.

Synthesis and characterization of NPs

NPs will be prepared following sol-gel routes and fully characterized using different techniques including electron microscopy, powder x-ray diffraction, porosimetry, etc.

Report on establishment of optimal collection, processing, storing and analysis of biological materials from patients

A report explaining the establishment of optimal collection processing storing and analysis of biological materials from pancreatic cancer patients

In vitro validation of the ULISES strategy

Validation of the cancer cells modification by targeted nanoparticles with the designed cargos.

In vivo validation of the ULISES strategy

Validation of pancreatic tumors modification by targeted nanoparticles with the designed cargos and evaluation of the therapeutic effect.

Production of transfection grade plasmid DNA (pDNA) to be used in T3.4 (assessment of pDNA effect in target cells)

Required amounts of pDNA will be produced following standard internal procedures

Constitution of the different management committees

The following committees will be formally constituted1 Project Management and Steering Committee PMSC 2 Scientific and Technical Committee STC3 Innovation and Exploitation Committee IXC4 Ethics Management Committee EMC

Websites, patent fillings, videos etc. (2)

Web site social media and logo

Launch of the project visual identity logo and other grapic elements the project website and social media channels Twitter account and LinkedIn page

Communication materials

Communication materials will include the project flyer a short presentation video an official power point presentation of the project a rollup poster

Open Research Data Pilot (2)

Data Management Plan

The Data Management Plan will provide the protocols to be followed in the management and treatment of data

Data Management Plan, final

The Data Management Plan will be updated.

Publikacje

Other (5)

A minimal miR-142T-transgene design detargets expression from myeloid cells in the absence of a sponge effect

Autorzy: Marta Parés, Aleix Angrill, Victor Pallaruelo-Santamaría, Cristina Fillat
Opublikowane w: 2025
Wydawca: manuscript in preparation

Evaluation of the efficacy of a monoclonal antibody for the treatment of pancreatic cancer by complement-dependent cytotoxicity

Autorzy: Ceballos-Francisco D., Ruiz Lorente I., Gimeno L., Martinez-Sanchez M.V., Parés Casellas M., Heidt S., Class F., Niemann M., Spierings E. Pallaruelo -Santamaria V., Fillat C, Minguela A
Opublikowane w: 2024
Wydawca: 7th European Congress of Immunology

Development of lipid nanoparticles loaded with nucleic acids for reprogramming cancer cells and restore immune-mediated cell death

Autorzy: Vicente Candela-Noguera, Javier Martínez-Latorre, Marta Parés, Alba García-Fernández, Elena Aznar, Cristina Fillat, Ramón Martínez-Máñez
Opublikowane w: 6th International Caparica Symposium on Nanoparticles/Nanomaterials and Applications 2024. Lisboa, 2024, ISBN 978-989-35197-2-1
Wydawca: Printed by: PROTEOMASS Scientific Society

Development of lipid nanoparticles loaded with nucleic acids for reprogramming cancer cells and restore immune-mediated cell death

Autorzy: Vicente Candela-Noguera, Javier Martínez-Latorre, Marta Parés, Alba García-Fernández, Elena Aznar, Cristina Fillat, Ramón Martínez-Máñez
Opublikowane w: XVI International Workshop on Sensors and Molecular Recognition. Valencia., 2023, ISBN 978-84-09-55991-6
Wydawca: Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico

Anti-CD47 multifunctionalized lipid nanoparticles target pancreatic cancer cells and promote macrophage phagocytosis.

Autorzy: Vicente Candela-Noguera, Marta Parés, Javier Martínez-Latorre, Alba García-Fernández, Elena Aznar, Victor Pallaruelo-Santamaría, Cristina Fillat, Ramón Martínez-Máñez
Opublikowane w: 2025
Wydawca: (manuscript in preparation)

Peer reviewed articles (4)

T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation

Autorzy: Emma T. M. Peereboom, Benedict M. Matern, Toshihide Tomosugi, Matthias Niemann, Julia Drylewicz, Irma Joosten, Wil A. Allebes, Arnold van der Meer, Luuk B. Hilbrands, Marije C. Baas, Franka E. van Reekum, Marianne C. Verhaar, Elena G. Kamburova, Marc A. J. Seelen, Jan Stephan Sanders, Bouke G. Hepkema, Annechien J. Lambeck, Laura B. Bungener, Caroline Roozendaal, Marcel G. J. Tilanus, Christien E.
Opublikowane w: Frontiers in Immunology, Numer 12, 2023, ISSN 1664-3224
Wydawca: Frontiers in Inmunology
DOI: 10.3389/fimmu.2021.784040

Peptides Derived From Mismatched Paternal Human Leukocyte Antigen Predicted to Be Presented by HLA-DRB1, -DRB3/4/5, -DQ, and -DP Induce Child-Specific Antibodies in Pregnant Women

Autorzy: Matthias Niemann, Benedict M. Matern, Eric Spierings, Stefan Schaub, Gideon Hönger
Opublikowane w: Frontiers in Immunology, Numer 12, 2021, ISSN 1664-3224
Wydawca: Frontiers in Immunology
DOI: 10.3389/fimmu.2021.797360

A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.

Autorzy: Jose Antonio Lopez Guerrero, Marcos Melián-Sosa, Zoraida Andreu Martínez, Raquel López-Reig, Antonio Fernández-Serra, Isidro Machado, Ricardo Yaya-Tur, María García-Flores, Marta Trallero-Anoro, Carmen Martínez-Lapiedra, Fernando Martínez de Juan, Marta Ramírez-Calvo, Tania Mazcuñan-Vitiello, Patricia Carretero-Hinojosa, Rafael Estevan
Opublikowane w: Journal of Clinical Oncology, Numer 42, 2024, Strona(/y) 681-681, ISSN 0732-183X
Wydawca: American Society of Clinical Oncology
DOI: 10.1200/jco.2024.42.3_suppl.681

A Comprehensive Transcriptional Signature in Pancreatic Ductal Adenocarcinoma Reveals New Insights into the Immune and Desmoplastic Microenvironments

Autorzy: Irene Pérez-Díez, Zoraida Andreu Marta R Hidalgo, Carla Perpiñá-Clérigues, Lucía Fantín, Antonio Fernandez-Serra, María de la Iglesia-Vaya, José A Lopez-Guerrero, Francisco García-García
Opublikowane w: Cancers (Basel), Numer 2023 May 24;15(11):2887, 2023, ISSN 2072-6694
Wydawca: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers15112887